Free Trial

IDEAYA Biosciences (IDYA) Competitors

IDEAYA Biosciences logo
$28.15
-1.31 (-4.45%)
(As of 10/31/2024 ET)

IDYA vs. CPRX, XENE, CUE, OSMT, SYRS, ROIV, LEGN, VKTX, LNTH, and ASND

Should you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Catalyst Pharmaceuticals (CPRX), Xenon Pharmaceuticals (XENE), Cue Biopharma (CUE), Osmotica Pharmaceuticals (OSMT), Syros Pharmaceuticals (SYRS), Roivant Sciences (ROIV), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Lantheus (LNTH), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.

IDEAYA Biosciences vs.

IDEAYA Biosciences (NASDAQ:IDYA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking.

Catalyst Pharmaceuticals has a net margin of 15.69% compared to IDEAYA Biosciences' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 27.77% beat IDEAYA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
IDEAYA BiosciencesN/A -20.52% -19.73%
Catalyst Pharmaceuticals 15.69%27.77%23.68%

IDEAYA Biosciences currently has a consensus target price of $55.45, indicating a potential upside of 95.54%. Catalyst Pharmaceuticals has a consensus target price of $29.50, indicating a potential upside of 35.38%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe IDEAYA Biosciences is more favorable than Catalyst Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEAYA Biosciences
0 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
3.07
Catalyst Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 3.5% of IDEAYA Biosciences shares are held by insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, IDEAYA Biosciences had 13 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 19 mentions for IDEAYA Biosciences and 6 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.70 beat IDEAYA Biosciences' score of 0.31 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IDEAYA Biosciences
3 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Catalyst Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Catalyst Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA Biosciences$11.96M180.34-$112.96M-$2.01-14.18
Catalyst Pharmaceuticals$434.48M5.93$71.41M$0.5440.39

IDEAYA Biosciences has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Catalyst Pharmaceuticals received 355 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. Likewise, 74.58% of users gave Catalyst Pharmaceuticals an outperform vote while only 71.43% of users gave IDEAYA Biosciences an outperform vote.

CompanyUnderperformOutperform
IDEAYA BiosciencesOutperform Votes
135
71.43%
Underperform Votes
54
28.57%
Catalyst PharmaceuticalsOutperform Votes
490
74.58%
Underperform Votes
167
25.42%

Summary

Catalyst Pharmaceuticals beats IDEAYA Biosciences on 11 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDYA vs. The Competition

MetricIDEAYA BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.16B$7.14B$5.37B$8.40B
Dividend YieldN/A8.77%5.21%4.20%
P/E Ratio-13.0116.47140.7317.73
Price / Sales180.34254.681,437.0778.19
Price / CashN/A50.1638.9433.56
Price / Book2.965.684.744.59
Net Income-$112.96M$151.16M$115.38M$225.45M
7 Day Performance-2.40%-1.43%-0.60%-0.22%
1 Month Performance-10.04%6.29%3.92%1.93%
1 Year Performance4.90%40.64%39.36%33.41%

IDEAYA Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDYA
IDEAYA Biosciences
4.3471 of 5 stars
$28.15
-4.4%
$55.45
+97.0%
+14.4%$2.13B$11.96M-12.8580Upcoming Earnings
Analyst Forecast
Short Interest ↓
CPRX
Catalyst Pharmaceuticals
4.7745 of 5 stars
$21.81
+1.2%
$29.50
+35.3%
+76.7%$2.58B$434.48M40.39167Upcoming Earnings
XENE
Xenon Pharmaceuticals
3.429 of 5 stars
$41.30
-1.4%
$57.45
+39.1%
+33.0%$3.12B$9.43M-15.07251Options Volume
Positive News
CUE
Cue Biopharma
4.6209 of 5 stars
$1.54
-12.0%
$5.00
+224.7%
-8.9%$74.91M$8.30M-1.5960Positive News
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/A$69.47M$177.88M-0.70302
SYRS
Syros Pharmaceuticals
4.5145 of 5 stars
$2.50
-0.4%
$5.00
+100.0%
+0.4%$66.82M$4.15M-0.58120
ROIV
Roivant Sciences
2.9572 of 5 stars
$11.64
-1.2%
$17.39
+49.4%
+39.4%$8.61B$158.30M2.09860
LEGN
Legend Biotech
1.9903 of 5 stars
$45.16
+2.0%
$82.08
+81.7%
-32.6%$8.23B$455.99M-57.901,800Analyst Forecast
VKTX
Viking Therapeutics
4.1451 of 5 stars
$73.37
+2.3%
$108.60
+48.0%
+649.0%$8.09BN/A-78.8920Insider Selling
Analyst Revision
LNTH
Lantheus
4.3315 of 5 stars
$108.91
-0.4%
$126.00
+15.7%
+77.6%$7.55B$1.44B17.85834Upcoming Earnings
News Coverage
Positive News
ASND
Ascendis Pharma A/S
3.0356 of 5 stars
$124.03
+1.0%
$195.92
+58.0%
+40.5%$7.22B$317.63M-13.32640Upcoming Earnings
Positive News

Related Companies and Tools


This page (NASDAQ:IDYA) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners